[go: up one dir, main page]

MXPA03010136A - Tratamiento del adhd. - Google Patents

Tratamiento del adhd.

Info

Publication number
MXPA03010136A
MXPA03010136A MXPA03010136A MXPA03010136A MXPA03010136A MX PA03010136 A MXPA03010136 A MX PA03010136A MX PA03010136 A MXPA03010136 A MX PA03010136A MX PA03010136 A MXPA03010136 A MX PA03010136A MX PA03010136 A MXPA03010136 A MX PA03010136A
Authority
MX
Mexico
Prior art keywords
treatment
adhd
tetrahydropyridin
indol
enantiomers
Prior art date
Application number
MXPA03010136A
Other languages
English (en)
Inventor
Klaus Peter Hertel
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of MXPA03010136A publication Critical patent/MXPA03010136A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Recrystallisation Techniques (AREA)

Abstract

La utilizacion del 3-[1-[2-(1-acetil-2,3-dihidro-lH- indol-3-il)etil]-1,2,3,6-tetrahidropiridin-4-il]-6-cloro-lH- indol, de cualquiera de sus enantiomeros y de las sales farmaceuticamente aceptables de los mismos, para la preparacion de una composicion farmaceutica para el tratamiento del deficit de la atencion-trastorno de la hiperactividad.
MXPA03010136A 2001-05-09 2002-05-07 Tratamiento del adhd. MXPA03010136A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100732 2001-05-09
PCT/DK2002/000298 WO2002089797A1 (en) 2001-05-09 2002-05-07 Treatment of adhd

Publications (1)

Publication Number Publication Date
MXPA03010136A true MXPA03010136A (es) 2004-03-10

Family

ID=8160484

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03010136A MXPA03010136A (es) 2001-05-09 2002-05-07 Tratamiento del adhd.

Country Status (23)

Country Link
US (1) US7294638B2 (es)
EP (1) EP1387682A1 (es)
JP (1) JP2004528361A (es)
KR (1) KR20040007544A (es)
CN (1) CN1507351A (es)
AR (1) AR033287A1 (es)
BG (1) BG108400A (es)
BR (1) BR0209443A (es)
CA (1) CA2446652A1 (es)
CO (1) CO5540378A2 (es)
CZ (1) CZ20033197A3 (es)
EA (1) EA200301221A1 (es)
HR (1) HRP20030852A2 (es)
HU (1) HUP0400075A2 (es)
IL (1) IL158413A0 (es)
IS (1) IS6992A (es)
MX (1) MXPA03010136A (es)
NO (1) NO20034972L (es)
NZ (1) NZ528896A (es)
PL (1) PL367778A1 (es)
SK (1) SK15002003A3 (es)
WO (1) WO2002089797A1 (es)
ZA (1) ZA200307955B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003236207A1 (en) * 2002-05-31 2003-12-19 H. Lundbeck A/S The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole
EP1812390A2 (en) * 2004-10-22 2007-08-01 Mark Froimowitz Methylphenidate analogs and methods of use thereof
WO2009136410A2 (en) 2008-04-19 2009-11-12 Nisarga Biotech Pvt. Ltd. Herbal composition for reducing add/adhd and method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521197A (en) 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
ZA9711376B (en) 1996-12-20 1998-07-21 Lundbeck & Co As H Indole or dihydroindole derivatives
WO2002046156A2 (en) * 2000-12-06 2002-06-13 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands

Also Published As

Publication number Publication date
CO5540378A2 (es) 2005-07-29
KR20040007544A (ko) 2004-01-24
EP1387682A1 (en) 2004-02-11
WO2002089797A8 (en) 2004-03-25
US20040152737A1 (en) 2004-08-05
ZA200307955B (en) 2004-10-13
HUP0400075A2 (hu) 2004-04-28
BR0209443A (pt) 2004-08-03
SK15002003A3 (sk) 2004-05-04
WO2002089797A1 (en) 2002-11-14
CN1507351A (zh) 2004-06-23
NZ528896A (en) 2004-12-24
US7294638B2 (en) 2007-11-13
NO20034972D0 (no) 2003-11-07
HRP20030852A2 (en) 2005-06-30
PL367778A1 (en) 2005-03-07
CA2446652A1 (en) 2002-11-14
JP2004528361A (ja) 2004-09-16
IL158413A0 (en) 2004-05-12
EA200301221A1 (ru) 2004-04-29
NO20034972L (no) 2003-11-07
AR033287A1 (es) 2003-12-10
CZ20033197A3 (en) 2004-06-16
BG108400A (bg) 2004-11-30
IS6992A (is) 2003-10-13

Similar Documents

Publication Publication Date Title
GEP20053600B (en) 3-(4-Amidopyrrol-2-Ylmethlidene)-2- Indolinone Derivatives as Protein Kinase Inhibitors
GEP20105053B (en) Bicyclic [3.1.0] heteroaryl amides as type i glycine transport inhibitors
MY136767A (en) Formulations comprising an indolinone compound
EP1399414A4 (en) SUBSTITUTED TETRACYCLINE COMPOUNDS FOR THE TREATMENT OF MALARIA
SG164283A1 (en) New benzimidazole derivatives
HUP0401564A3 (en) Diaryl cycloalkyl derivatives, the use thereof as ppar activators and pharmaceutical compositions containing thereof
HRP20030910A2 (en) Tartarate salts 5,8,14-triazatetracyclo {10.3.1.0&lt;sup&gt;2,11&lt;/sup&gt;.0&lt;sup&gt;4,9&lt;/sup&gt;}-hexadeca-2(11), 3,5,7,9-pentaene and pharmaceutical compositions thereof
ATE454378T1 (de) Verbindungen, die sich als inhibitoren vonjak und anderen proteinkinasen eignen
MX2010004688A (es) Usos terapeuticos de compuestos que tienen actividad combinada de sert, 5- ht3 y 5-ht1a.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
EP2295055A3 (en) (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: Methods of using and compositions thereof
EP1686967A4 (en) CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
AR018197A1 (es) Compuestos de piperidina, un procedimiento para su preparacion, una composicion y uso del mismo para la preparacion de un medicamento
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
SI1185272T1 (en) Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
YU88103A (sh) Lecenje adhd
SE9903997D0 (sv) New compounds
MXPA04001209A (es) Farmaco con efecto neuroprotector.
IL152793A0 (en) PROCESS FOR THE SYNTHESIS OF (2R, 2-ALPHA-R, 3a)-2-[1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL]-3-(4-FLUOROPHENYL)-1,4-OXAZINE
GEP20094801B (en) Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
NZ502495A (en) Use of a specific antagonist of 5HT2 receptor antagonist for the preparation of medicines useful in the treatment of sleep apnoea syndrome
MXPA03010136A (es) Tratamiento del adhd.
PL370412A1 (en) Pseudopolymorphic forms of carvedilol
MX2021008321A (es) Composiciones farmaceuticas que comprenden (s)-4-(4-(4-(((2-(2,6-d ioxopiperidin-3-il)-1-oxoisoindolin-4-il)oxi)metil)bencil)piperaz in-1-il)-3-fluorobenzonitrilo y metodos para su uso.